Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study
FY 2022-23
Summary
Colorectal and pancreatic cancers are both deadly cancers, ranking in the top three of the leading cause of cancer death in Canada. They are responsible for a significant increase in healthcare expenditure. Smoking, alcohol abuse, and inappropriate dietary habits are common risk factors for both cancers, but medications such as anticoagulants may play a role in their occurrence, although their contribution has not been fully explored. Direct oral anticoagulants (DOACs) are a specific type of anticoagulants, recently introduced in clinical practice in the prevention of thrombosis in non-valvular atrial fibrillation. These drugs present a reasonable drug-drug interaction profile, don't require regular monitoring, and are orally administered, all of which make them more attractive and widely used compared to conventional anticoagulants such as warfarin or heparins. However, few animals studies have signaled an increased risk of colorectal and pancreatic cancers with these drugs. These results have prompted several studies in humans which have resulted in mixed findings, some studies have found a greater risk of both cancers while others have not. Further, these studies had notable problems including residual bias, confounding by indication, and insufficient power. The primary objective of this study is to separately assess the risk of CRC and PC among DOACs users compared to non-users. Secondarily, I will assess separately the risk of CRC and PC compared to VKAs. Additionally, I will assess the risk of CRC and PC associated with concurrent use of proton pump inhibitors and DOACs compared to the use of DOACs alone. I will use the Clinical Practice Research Datalink (CPRD), a primary care database that contains anonymized medical records of over 60 million patients over around 2500 general practices. My role in the project includes scientific literature review; study design, development of scientific and technical protocols; and analysis of the administrative databases.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475845
Name
Damba Joseph Junior
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Anticoagulants; Cohort Study; Colorectal Cancer; Direct Oral Anticoagulants; Pancreatic Cancer; Vitamins K Antagonists
Abstract
Colorectal and pancreatic cancers are both deadly cancers, ranking in the top three of the leading cause of cancer death in Canada. They are responsible for a significant increase in healthcare expenditure. Smoking, alcohol abuse, and inappropriate dietary habits are common risk factors for both cancers, but medications such as anticoagulants may play a role in their occurrence, although their contribution has not been fully explored. Direct oral anticoagulants (DOACs) are a specific type of anticoagulants, recently introduced in clinical practice in the prevention of thrombosis in non-valvular atrial fibrillation. These drugs present a reasonable drug-drug interaction profile, don't require regular monitoring, and are orally administered, all of which make them more attractive and widely used compared to conventional anticoagulants such as warfarin or heparins. However, few animals studies have signaled an increased risk of colorectal and pancreatic cancers with these drugs. These results have prompted several studies in humans which have resulted in mixed findings, some studies have found a greater risk of both cancers while others have not. Further, these studies had notable problems including residual bias, confounding by indication, and insufficient power. The primary objective of this study is to separately assess the risk of CRC and PC among DOACs users compared to non-users. Secondarily, I will assess separately the risk of CRC and PC compared to VKAs. Additionally, I will assess the risk of CRC and PC associated with concurrent use of proton pump inhibitors and DOACs compared to the use of DOACs alone. I will use the Clinical Practice Research Datalink (CPRD), a primary care database that contains anonymized medical records of over 60 million patients over around 2500 general practices. My role in the project includes scientific literature review; study design, development of scientific and technical protocols; and analysis of the administrative databases.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Damba, Joseph Junior
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~